# Phase 2 Lymphoma, T-Cell, Peripheral trials: 23 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials in phase 2 for Lymphoma, T-Cell, Peripheral that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Lymphoma, T-Cell, Peripheral trials: 23 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/lymphoma-t-cell-peripheral

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 23
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 5, 2026 | NCT07920393 | Allogeneic Cell Therapy in Refractory T-Cell Lymphoma | University Medical Center Goettingen | Phase 2 | Not yet recruiting | Lymphoma, T Cell, Peripheral | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920393) |
| August 5, 2026 | NCT07746245 | The Efficacy of CAPCT in Patients With PTCL | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Not yet recruiting | Peripheral T-Cell Lymphoma | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746245) |
| April 17, 2026 | NCT07535762 | Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma | Shanghai Jiao Tong University School of Medicine | Phase 2 | Not yet recruiting | Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL)... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07535762) |
| January 21, 2026 | NCT07356245 | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | Ohio State University Comprehensive Cancer Center | Phase 2 | Recruiting | T-cell Lymphoma, Graft Versus Host Disease, Lymphoma, T-Cell, Peripheral T Cell Lymphoma, T-cell Prolymphocytic... | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07356245) |
| December 16, 2025 | NCT07283822 | Amping up With PemJAK | Sponsor not shown (see the record) | Phase 2 | Recruiting | Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Hodgkin Disease Recurrent... | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07283822) |
| December 12, 2025 | NCT07279584 | Golidocitinib Combined With GemOx in RR PTCL | Ruijin Hospital | Phase 2 | Not yet recruiting | Peripheral T-cell Lymphomas (PTCL) | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07279584) |
| September 18, 2025 | NCT07180771 | A Study of Bosmolisib (BR101801) in Participants With R/R PTCL. | Boryung Pharmaceutical Co., Ltd | Phase 2 | Not yet recruiting | Peripheral T Cell Lymphoma | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07180771) |
| July 23, 2025 | NCT07081607 | Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma. | Ruijin Hospital | Phase 2 | Not yet recruiting | Peripheral T-Cell Lymphoma, Not Classified | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07081607) |
| June 24, 2025 | NCT07032532 | Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23) | Sun Yat-sen University | Phase 2 | Not yet recruiting | Peripheral T Cell Lymphoma | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07032532) |
| November 25, 2024 | NCT06702605 | To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma | Evopoint Biosciences Inc. | Phase 2 | Not yet recruiting | Relapsed/Refractory Peripheral T Cell Lymphoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06702605) |
| October 8, 2024 | NCT06630091 | A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed... | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Peripheral T Cell Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06630091) |
| July 25, 2024 | NCT06519526 | Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma | Fudan University | Phase 2 | Recruiting | Relapsed/Refractory Peripheral T Cell Lymphoma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06519526) |
| February 6, 2024 | NCT06244368 | GVM±R in Patients With Relapsed or Refractory Aggressive NHL. | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06244368) |
| December 7, 2023 | NCT06160843 | Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma | National Cancer Centre, Singapore | Phase 2 | Recruiting | Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06160843) |
| November 30, 2023 | NCT06151106 | Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma | The First Affiliated Hospital of Xiamen University | Phase 2 | Recruiting | Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06151106) |
| August 4, 2023 | NCT05976997 | Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell... | Sponsor not shown (see the record) | Phase 2 | Recruiting | Newly Diagnosed Peripheral T-cell Lymphoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05976997) |
| July 25, 2023 | NCT05958719 | Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated... | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Peripheral T Cell Lymphoma, Epigenetic Repression | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05958719) |
| April 27, 2023 | NCT05833724 | Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) | Great Novel Therapeutics Biotech & Medicals Corporation | Phase 2 | Recruiting | Relapsed or Refractory Peripheral T-cell Lymphoma | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05833724) |
| April 6, 2022 | NCT05313243 | Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma | Yale University | Phase 2 | Recruiting | T-Cell Lymphoma | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05313243) |
| January 10, 2022 | NCT05182957 | Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma | The First Affiliated Hospital of Soochow University | Phase 2 | Recruiting | Relapsed/Refractory Peripheral T-cell Lymphoma | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05182957) |
| June 10, 2021 | NCT04922567 | Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Recruiting | Peripheral T-Cell Lymphoma, Lenalidomide, CHOP | 289 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04922567) |
| August 13, 2020 | NCT04512534 | Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma | Fudan University | Phase 2 | Recruiting | Peripheral T-cell Lymphoma | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04512534) |
| September 10, 2019 | NCT04083495 | CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma | UNC Lineberger Comprehensive Cancer Center | Phase 2 | Recruiting | Peripheral T Cell Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04083495) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fudan University | 2 |
| Ruijin Hospital | 2 |
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| The First Affiliated Hospital of Xiamen University | 1 |
| Ohio State University Comprehensive Cancer Center | 1 |
| [Boryung Pharmaceutical Co., Ltd](https://specstream.ai/data/clinical-trials/company/boryung-pharmaceutical-co-ltd) | 1 |
| University Medical Center Goettingen | 1 |
| Shanghai Jiao Tong University School of Medicine | 1 |
| Sun Yat-sen University | 1 |
| [Evopoint Biosciences Inc.](https://specstream.ai/data/clinical-trials/company/evopoint-biosciences-inc) | 1 |
| Yale University | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| National Cancer Centre, Singapore | 1 |
| M.D. Anderson Cancer Center | 1 |
| Great Novel Therapeutics Biotech & Medicals Corporation | 1 |
| The First Affiliated Hospital of Soochow University | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 11 |
| United States | 5 |
| Singapore | 1 |
| Taiwan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Gastropubs in the United States](https://specstream.ai/data/businesses/gastropubs/united-states)
- [Landscape architecture firms in the United States](https://specstream.ai/data/businesses/landscape-architecture-firms/united-states)
- [Pathology practices in the United States](https://specstream.ai/data/businesses/pathology-practices/united-states)
- [Screen printers in the United States](https://specstream.ai/data/businesses/screen-printers/united-states)
- [Vehicle manufacturers in the United States](https://specstream.ai/data/businesses/vehicle-manufacturers/united-states)
- [B2B medical support companies in the United States](https://specstream.ai/data/businesses/b2b-medical-support-companies/united-states)
